nach oben

Erschienen in:

01.10.2016 | Original Article

Chemotherapy-Induced Neurotoxicity: Evidence of a Protective Role of CC Homozygosis in the Interleukin-1β Gene-511 C>T Polymorphism

verfasst von: E. Peila, F. D’Agata, P. Caroppo, L. Orsi, P. Mortara, S. Cauda, M. Manfredi, M.M. Caglio, P. Fenoglio, B. Baudino, G. Castellano, G. Bisi, L. Pinessi, S. Gallone

Erschienen in: Neurotoxicity Research | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

We hypothesized that the IL-1β-511 C>T polymorphism could be associated with the development of neurotoxicity and that it could be a possible biomarker to rate the risk of occurrence of neurotoxicity in cancer patients. Genomic DNA was extracted from 85 cancer patients: 49 received systemic chemotherapeutic treatment (CHT) and 36 patients did not receive it (No-CHT). All subjects were genotyped for the functionally active polymorphisms of IL-1β-511 C>T. We estimated neurotoxicity with the evaluation of neurological deficits. CHT patients showed erythrocytopenia, neurological deficit and a slight lowering of cognitive performance. The subgroup of patients carrying the CC genotype of the IL-1β-511 C>T gene showed lesser neurological deficits. In the context of cancer treatment, we suggested the potential value of IL-1β-511 C>T as genetic biomarkers to identify patients with higher risk to develop neurological deficits.

Ahles TA, Saykin AJ, Furstenberg CT et al (2002) Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 20:485–493. doi:10.1200/JCO.20.2.485 CrossRefPubMed

Arend WP (2002) The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev 13:323–340CrossRefPubMed

Argyriou AA, Iconomou G, Kalofonos HP (2008a) Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 112:1593–1599CrossRefPubMed

Argyriou AA, Polychronopoulos P, Iconomou G et al (2008b) A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat Rev 34:368–377CrossRefPubMed

Argyriou AA, Bruna J, Marmiroli P, Cavaletti G (2012) Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol 82:51–77CrossRefPubMed

Baudino B, D’agata F, Caroppo P et al (2012) The chemotherapy long-term effect on cognitive functions and brain metabolism in lymphoma patients. Q J Nucl Med Mol imaging 56:559–568PubMed

Bower JE, Ganz PA, Irwin MR et al (2013) Cytokine genetic variations and fatigue among patients with breast cancer. J Clin Oncol 31:1656–1661. doi:10.1200/JCO.2012.46.2143 CrossRefPubMedPubMedCentral

Cavaletti G, Marmiroli P (2010) Chemotherapy-induced peripheral neurotoxicity. Nat Rev Neurol 6:657–666. doi:10.1517/14740338.3.6.535 CrossRefPubMed

Cavaletti G, Marmiroli P (2015) Chemotherapy-induced peripheral neurotoxicity. Curr Opin Neurol 28:500–507. doi:10.1097/WCO.0000000000000234 CrossRefPubMed

Cavaletti G, Cavalletti E, Oggioni N et al (2000) Distribution of paclitaxel within the nervous system of the rat after repeated intravenous administration. Neurotoxicology 21:389–393PubMed

Cavaletti G, Alberti P, Marmiroli P (2011) Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics. Lancet Oncol 12:1151–1161CrossRefPubMed

Cavallone L, Bonafè M, Olivieri F et al (2003) The role of IL-1 gene cluster in longevity: a study in Italian population. Mech Ageing Dev 124:533–538CrossRefPubMed

Cleeland CS, Bennett GJ, Dantzer R et al (2003) Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? a cytokine-immunologic model of cancer symptoms. Cancer 97:2919–2925. doi:10.1002/cncr.11382 CrossRefPubMed

del Rey A, Apkarian AV, Martina M, Besedovsky HO (2012) Chronic neuropathic pain-like behavior and brain-borne IL-1β. Ann N Y Acad Sci 1262:101–107. doi:10.1111/j.1749-6632.2012.06621.x CrossRefPubMedPubMedCentral

Déniz-Naranjo MC, Muñoz-Fernandez C, Alemany-Rodríguez MJ et al (2008) Cytokine IL-1 beta but not IL-1 alpha promoter polymorphism is associated with Alzheimer disease in a population from the Canary Islands, Spain. Eur J Neurol 15:1080–1084. doi:10.1111/j.1468-1331.2008.02252.x CrossRefPubMed

Di Bona D, Plaia A, Vasto S et al (2008) Association between the interleukin-1beta polymorphisms and Alzheimer’s disease: a systematic review and meta-analysis. Brain Res Rev 59:155–163. doi:10.1016/j.brainresrev.2008.07.003 CrossRefPubMed

di Giovine FS, Takhsh E, Blakemore AI, Duff GW (1992) Single base polymorphism at -511 in the human interleukin-1 beta gene (IL1 beta). Hum Mol Genet 1:450. doi:10.1093/hmg/1.6.450 CrossRefPubMed

Dinarello CA (1994) The biological properties of interleukin-1. Eur Cytokine Netw 5:517–531PubMed

El-Omar EM, Carrington M, Chow WH et al (2000) Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 404:398–402. doi:10.1038/35006081 CrossRefPubMed

Forlenza OV, Diniz BS, Talib LL et al (2009) Increased serum IL-1beta level in Alzheimer’s disease and mild cognitive impairment. Dement Geriatr Cogn Disord 28:507–512. doi:10.1159/000255051 CrossRefPubMed

Ganz PA, Bower JE, Kwan L et al (2013) Does tumor necrosis factor-alpha (TNF-α) play a role in post-chemotherapy cerebral dysfunction? Brain Behav Immun 30(Suppl):S99–S108. doi:10.1016/j.bbi.2012.07.015 CrossRefPubMed

Green EK, Harris JM, Lemmon H et al (2002) Are interleukin-1 gene polymorphisms risk factors or disease modifiers in AD? Neurology 58:1566–1568. doi:10.1212/WNL.58.10.1566 CrossRefPubMed

Griffin WS (2006) Inflammation and neurodegenerative diseases. Am ClinNutr 83:470S–474S

Grimaldi LM, Casadei VM, Ferri C et al (2000) Association of early-onset Alzheimer’s disease with an interleukin-1alpha gene polymorphism. Ann Neurol 47:361–365CrossRefPubMed

Hall SK, Perregaux DG, Gabel CA et al (2004) Correlation of polymorphic variation in the promoter region of the interleukin-1β gene with secretion of interleukin-1β protein. Arthritis Rheum 50:1976–1983. doi:10.1002/art.20310 CrossRefPubMed

Hausheer FH, Schilsky RL, Bain S et al (2006) Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol 33:15–49CrossRefPubMed

Henderson ST, Poirier J (2011) Pharmacogenetic analysis of the effects of polymorphisms in APOE, IDE and IL1B on a ketone body based therapeutic on cognition in mild to moderate Alzheimer’s disease; a randomized, double-blind, placebo-controlled study. BMC Med Genet 12:137CrossRefPubMedPubMedCentral

Huang D, Pirskanen R, Hjelmström P, Lefvert AK (1998) Polymorphisms in IL-1beta and IL-1 receptor antagonist genes are associated with myasthenia gravis. J Neuroimmunol 81:76–81CrossRefPubMed

Huang D, Zheng C, Giscombe R et al (1999) Polymorphisms at -174 and in the 3′ flanking region of interleukin-6 (IL-6) gene in patients with myasthenia gravis. J Neuroimmunol 101:197–200. doi:10.1016/S0165-5728(99)00140-X CrossRefPubMed

Inagaki M, Yoshikawa E, Matsuoka Y et al (2007) Smaller regional volumes of brain gray and white matter demonstrated in breat cancer survivors exposed to adjuvant chemotherapy. Cancer 109:146–156. doi:10.1002/cncr.22368 CrossRefPubMed

Licastro F, Pedrini S, Ferri C et al (2000) Gene polymorphism affecting alpha1-antichymotrypsin and interleukin-1 plasma levels increases Alzheimer’s disease risk. Ann Neurol 48:388–391CrossRefPubMed

Miller RJ, Jung H, Bhangoo SK, White FA (2009) Cytokine and chemokine regulation of sensory neuron function. Handb Exp Pharmacol 194:417–449. doi:10.1007/978-3-540-79090-7_12 CrossRefPubMed

Miller BJ, Buckley P, Seabolt W et al (2011) Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 70:663–671. doi:10.1016/j.biopsych.2011.04.013 CrossRefPubMedPubMedCentral

Natori A, Ogata T, Sumitani M et al (2015) Potential role of pNF-H, a biomarker of axonal damage in the central nervous system, as a predictive marker of chemotherapy-induced cognitive impairment. Clin Cancer Res 21:1348–1352. doi:10.1158/1078-0432.CCR-14-2775 CrossRefPubMed

Nicklin MJ, Weith A, Duff GW (1994) A physical map of the region encompassing the human interleukin-1 alpha, interleukin-1 beta, and interleukin-1 receptor antagonist genes. Genomics 19:382–384CrossRefPubMed

O’Farrell E, MacKenzie J, Collins B (2013) Clearing the air: a review of our current understanding of “chemo fog”. Curr Oncol Rep 15:260–269. doi:10.1007/s11912-013-0307-7 CrossRefPubMed

Pettersson CAV, Sharma HS, Olsson Y (1990) Vascular permeability of spinal nerve roots. a study in the rat with evans blue and lanthanum as tracers. Acta Neuropathol 81:148–154. doi:10.1007/BF00334503 CrossRefPubMed

Pociot F, Mølvig J, Wogensen L et al (1992) A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro. Eur J Clin Invest 22:396–402CrossRefPubMed

Poli F, Nocco A, Berra S et al (2002) Allele frequencies of polymorphisms of TNFA, IL-6, IL-10 and IFNG in an Italian caucasian population. Eur J Immunogenet 29:237–240. doi:10.1046/j.1365-2370.2002.00303.x CrossRefPubMed

Ren K, Torres R (2009) Role of interleukin-1beta during pain and inflammation. Brain Res Rev 60:57–64CrossRefPubMed

Rothwell NJ, Strijbos PJ (1995) Cytokines in neurodegeneration and repair. Int J Dev Neurosci 13:179–185CrossRefPubMed

Santtila S, Savinainen K, Hurme M (1998) Presence of the IL-1RA allele 2 (IL1RN*2) is associated with enhanced IL-1beta production in vitro. Scand J Immunol 47:195–198. doi:10.1046/j.1365-3083.1998.00300.x CrossRefPubMed

Schäfers M, Sorkin L (2008) Effect of cytokines on neuronal excitability. NeurosciLett 437:188–193. doi:10.1016/j.neulet.2008.03.052

Seretny M, Currie GL, Sena ES et al (2014) Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain 155:2461–2470. doi:10.1016/j.pain.2014.09.020 CrossRefPubMed

Seripa D, Dobrina A, Margaglione M et al (2003) Relevance of interleukin-1 receptor antagonist intron-2 polymorphism in ischemic stroke. Cerebrovasc Dis 15:276–281. doi:10.1159/000069497 CrossRefPubMed

Shafia S, Dilafroze Sofi FA et al (2014) Rheumatoid arthritis and genetic variations in cytokine genes: a population-based study in Kashmir Valley. Immunol Invest 43:349–359. doi:10.3109/08820139.2013.879171 CrossRefPubMed

Skundric DS, Dai R, James J, Lisak RP (2002) Activation of IL-1 signaling pathway in schwann cells during diabetic neuropathy. Ann N Y Acad Sci 958:393–398CrossRefPubMed

Smith EML, Beck SL, Cohen J (2008) The total neuropathy score: a tool for measuring chemotherapy-induced peripheral neuropathy. Oncol Nurs Forum 35:96–102. doi:10.1188/08.ONF.96-102 CrossRefPubMed

Smith JA, Das A, Ray SK, Banik NL (2012) Role of pro-inflammatory cytokines released from microglia in neurodegenerative diseases. Brain Res Bull 87:10–20. doi:10.1016/j.brainresbull.2011.10.004 CrossRefPubMed

Sommer C, Kress M (2004) Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia. Neurosci Lett 361:184–187CrossRefPubMed

Spinnler H, Tognoni G (1987) Standardizzazione e taratura italiana di test neuropsicologici

Stefanidis I, Kreuer K, Dardiotis E et al (2014) Association between the interleukin-1β gene (IL1B) C-511T polymorphism and the risk of diabetic nephropathy in type 2 diabetes: a candidate-gene association study. DNA Cell Biol 33:463–468. doi:10.1089/dna.2013.2204 CrossRefPubMed

Vezzani A, Viviani B (2015) Neuromodulatory properties of inflammatory cytokines and their impact on neuronal excitability. Neuropharmacology 96:70–82. doi:10.1016/j.neuropharm.2014.10.02 CrossRefPubMed

Vichaya EG, Chiu GS, Krukowski K et al (2015) Mechanisms of chemotherapy-induced behavioral toxicities. Front Neurosci 9:131. doi:10.3389/fnins.2015.00131 CrossRefPubMedPubMedCentral

Wang XM, Lehky TJ, Brell JM, Dorsey SG (2012) Discovering cytokines as targets for chemotherapy-induced painful peripheral neuropathy. Cytokine 59:3–9CrossRefPubMedPubMedCentral

Wang X-M, Walitt B, Saligan L et al (2015) Chemobrain: a critical review and causal hypothesis of link between cytokines and epigenetic reprogramming associated with chemotherapy. Cytokine 72:86–96. doi:10.1016/j.cyto.2014.12.006 CrossRefPubMedPubMedCentral

Weisman D, Hakimian E, Ho GJ (2006) Interleukins, inflammation, and mechanisms of Alzheimer’s disease. Vitam Horm 74:505–530CrossRefPubMed

Wilkes G (2007) Peripheral neuropathy related to chemotherapy. Semin Oncol Nurs 23:162–173. doi:10.1016/j.soncn.2007.05.001 CrossRefPubMed

Wilson AG, di Giovine FS, Blakemore AI, Duff GW (1992) Single base polymorphism in the human tumour necrosis factor alpha (TNF alpha) gene detectable by NcoI restriction of PCR product. Hum Mol Genet 1:353. doi:10.1093/hmg/1.5.353 CrossRefPubMed

Windebank AJ, Grisold W (2008) Chemotherapy-induced neuropathy. J Peripher Nerv Syst 13:27–46. doi:10.1111/j.1529-8027.2008.00156.x CrossRefPubMed

Titel: Chemotherapy-Induced Neurotoxicity: Evidence of a Protective Role of CC Homozygosis in the Interleukin-1β Gene-511 C>T Polymorphism
verfasst von: E. Peila
F. D’Agata
P. Caroppo
L. Orsi
P. Mortara
S. Cauda
M. Manfredi
M.M. Caglio
P. Fenoglio
B. Baudino
G. Castellano
G. Bisi
L. Pinessi
S. Gallone
Publikationsdatum: 01.10.2016
Verlag: Springer US
Erschienen in: Neurotoxicity Research / Ausgabe 3/2016
Print ISSN: 1029-8428
Elektronische ISSN: 1476-3524
DOI: https://doi.org/10.1007/s12640-016-9637-1

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

23.04.2024 | Demenz | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Chemotherapy-Induced Neurotoxicity: Evidence of a Protective Role of CC Homozygosis in the Interleukin-1β Gene-511 C>T Polymorphism

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Neurologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2016

DADS Analogues Ameliorated the Cognitive Impairments of Alzheimer-Like Rat Model Induced by Scopolamine

Biochanin A Protects Against Lipopolysaccharide-Induced Damage of Dopaminergic Neurons Both In Vivo and In Vitro via Inhibition of Microglial Activation

β-Ecdysterone Protects SH-SY5Y Cells Against 6-Hydroxydopamine-Induced Apoptosis via Mitochondria-Dependent Mechanism: Involvement of p38MAPK–p53 Signaling Pathway

Frequency of Spontaneous BOLD Signal Differences between Moderate and Late Preterm Newborns and Term Newborns

Neuroprotective Effect of the Novel Compound ITH33/IQM9.21 Against Oxidative Stress and Na+ and Ca2+ Overload in Motor Neuron-like NSC-34 Cells

Transient Receptor Potential Channels in Microglia: Roles in Physiology and Disease

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Neurologie